Deutsche Bank AG Boosts Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Deutsche Bank AG boosted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 16.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,589,607 shares of the company’s stock after purchasing an additional 375,064 shares during the period. Deutsche Bank AG owned about 0.23% of Teva Pharmaceutical Industries worth $39,802,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of TEVA. Russell Investments Group Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 33.8% in the fourth quarter. Russell Investments Group Ltd. now owns 204,447 shares of the company’s stock valued at $4,506,000 after acquiring an additional 51,601 shares in the last quarter. Cerity Partners LLC lifted its holdings in Teva Pharmaceutical Industries by 15.2% in the 4th quarter. Cerity Partners LLC now owns 47,712 shares of the company’s stock worth $981,000 after purchasing an additional 6,311 shares in the last quarter. Raymond James Financial Inc. bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth approximately $38,914,000. Townsquare Capital LLC grew its holdings in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock valued at $885,000 after buying an additional 812 shares in the last quarter. Finally, Mariner LLC grew its holdings in Teva Pharmaceutical Industries by 10.6% during the 4th quarter. Mariner LLC now owns 59,356 shares of the company’s stock valued at $1,308,000 after buying an additional 5,689 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.0%

Shares of TEVA stock opened at $16.58 on Wednesday. The company has a market cap of $19.02 billion, a PE ratio of -103.63, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The stock’s 50 day simple moving average is $16.69 and its two-hundred day simple moving average is $16.32. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business’s revenue for the quarter was up .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 earnings per share. Research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

TEVA has been the topic of several research analyst reports. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a “buy” rating and a $25.00 target price for the company. UBS Group decreased their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and an average price target of $24.71.

Insider Activity

In related news, insider Placid Jover sold 6,053 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 65,001 shares of company stock valued at $996,958. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.